Viking Therapeutics Inc represents values of innovation, integrity, and patient-centricity. As a biopharmaceutical company, Viking Therapeutics is committed to developing novel treatments for metabolic and endocrine disorders. The company's corporate philosophy emphasizes a research-driven approach, ensuring the highest quality in drug discovery and development. Viking strives for transparency and ethical practices in all aspects of its operations. With a focus on improving patients' lives through therapeutic advancements, Viking Therapeutics remains dedicated to revolutionizing the treatment options available in the healthcare industry.

Viking Therapeutics Inc, a renowned pharmaceutical company, primarily operates in the United States. With a strong focus on the development of novel therapies for metabolic and endocrine disorders, Viking Therapeutics actively engages in clinical research and collaboration within the US market. By leveraging innovative approaches and strategic partnerships, Viking Therapeutics Inc aims to address critical medical needs and improve patients' lives. With its headquarters based in San Diego, California, Viking Therapeutics remains committed to advancing transformative treatments within the domestic pharmaceutical landscape.

Viking Therapeutics Inc has achieved several significant milestones. Firstly, the company successfully completed Phase 2 clinical trials for its lead product candidate VK2809, demonstrating its potential to treat fatty liver disease. Additionally, Viking Therapeutics received FDA orphan drug designation for VK2809 in the treatment of glycogen storage disease type Ia. The company also announced positive results from Phase 2 clinical trials for VK5211, a potential treatment for muscle loss. Viking Therapeutics' achievements demonstrate its dedication to advancing innovative therapies in areas of high unmet medical needs, making it a promising player in the pharmaceutical industry.

Viking Therapeutics Inc is a biopharmaceutical company specializing in the development of novel therapies for metabolic and endocrine disorders. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California. The company is dedicated to advancing its pipeline of innovative drug candidates, aiming to address the significant unmet medical needs in areas like non-alcoholic steatohepatitis (NASH) and hip fracture recovery. Viking Therapeutics' research focuses on the role of specific receptors in modulating metabolic and hormonal pathways, targeting diseases that affect millions worldwide. With a strong commitment to scientific excellence, Viking Therapeutics strives to deliver groundbreaking treatments to improve patient outcomes and quality of life.

The main competitors of Viking Therapeutics Inc in the market include Amgen Inc, Intercept Pharmaceuticals Inc, and Gilead Sciences Inc.

Viking Therapeutics Inc is primarily active in the pharmaceutical industry, specifically focusing on the development of novel therapies for metabolic and endocrine disorders. With a strong emphasis on addressing unmet medical needs, Viking Therapeutics aims to provide innovative solutions for patients suffering from conditions like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Through their extensive research and development efforts, Viking Therapeutics is committed to improving the lives of individuals affected by these diseases.

The business model of Viking Therapeutics Inc revolves around developing novel therapeutics for metabolic and endocrine disorders. The company focuses on researching and developing small molecule drugs that target specific biological pathways to address conditions such as non-alcoholic steatohepatitis (NASH), hip fracture recovery, and other metabolic diseases. Viking Therapeutics aims to provide innovative solutions to unmet medical needs by advancing its pipeline of drug candidates through rigorous scientific research and clinical trials. By leveraging its expertise in drug discovery and development, Viking Therapeutics strives to improve the lives of patients and deliver value to its stakeholders.

Viking Therapeutics hissesinin F/K oranı -38,46.

Viking Therapeutics KUV 0 dir.

Viking Therapeutics için AlleAktien Kalite Skoru 4/10'dur.

Viking Therapeutics için şu an ciro hesaplanamıyor.

beklenen Viking Therapeutics karı -125,77 Milyon. USD olarak gerçekleşmiştir.

Viking Therapeutics Inc. is a biopharmaceutical company focused on the development of drugs for metabolic and endocrine diseases. The company was founded in 2012 and is headquartered in San Diego, California. Viking Therapeutics currently offers two main products: VK2809 and VK5211. VK2809 is a selective thyroid hormone receptor beta agonist developed for the treatment of fatty liver disease and hypercholesterolemia. VK5211 is a selective androgen receptor modulator used for the treatment of muscle wasting and weakness, as well as for supporting rehabilitation measures. Both VK2809 and VK5211 are still in various stages of clinical development and have shown promising results. In clinical studies, VK2809 has shown the ability to achieve significant improvements in liver function and cholesterol levels. VK5211 has also shown positive results in clinical studies by increasing muscle strength and mass in patients with muscle wasting. Viking Therapeutics has also entered into a research collaboration with Ligand Pharmaceuticals, a leading provider of ligand technology. The partnership aims to discover and develop additional potential drug candidates that address a broader range of diseases. The business model of Viking Therapeutics is based on the development and commercialization of new drugs targeting specific disease areas. The company uses an innovative scientific approach to develop potential therapies that build on existing biological processes in the body. These drugs are specifically tailored to the needs of patients with metabolic and endocrine disorders. In addition, Viking Therapeutics relies on careful selection of study centers for conducting clinical trials. The company selects centers that have extensive experience in clinical research and adhere to the strictest standards for conducting clinical trials. Viking Therapeutics primarily finances its research and development projects through equity and debt financing. As part of its business strategy, the company also seeks partnerships and licensing agreements with other companies to expand the distribution of its products and services. In summary, Viking Therapeutics' business model is focused on developing and marketing novel therapies for metabolic and endocrine diseases. Through collaboration with various research institutions and leveraging its scientific expertise, the company is able to develop promising medical solutions for patients with severe metabolic disorders and other conditions.

Viking Therapeutics, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Viking Therapeutics için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Viking Therapeutics şirketinin ISIN kodu US92686J1060’dir.

Viking Therapeutics 'nin WKN'si A12GD6 'dir.

Viking Therapeutics için Ticker VKTX’dir.

Son 12 ay içerisinde Viking Therapeutics, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Viking Therapeutics, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Viking Therapeutics şirketinin mevcut temettü verimi .

Viking Therapeutics dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Viking Therapeutics, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Viking Therapeutics, 'Sağlık' sektörüne atanmıştır.

Son Viking Therapeutics tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 08.07.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 08.07.2024 olarak gerçekleşti.

2023 yılında Viking Therapeutics tarafından 0 USD olarak temettüler dağıtıldı.

Viking Therapeutics hisselerinin temettüleri USD olarak dağıtılır.